MCL1 and plasma cell myeloma: USP9X can bind and remove polyubiquitin chains from MCL1 targeted for degradation, and its expression correlates with MCL1 overexpression in follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.